Realm Therapeutics Provides Clinical Update, including Results from a Phase 2 Study of PR013 in Allergic Conjunctivitis

MALVERN, Pa., March 12, 2018 /PRNewswire/ — Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today provides an update on the Company’s clinical programs.  
The Company reports that…


Source: https://www.prnewswire.com/news-releases/realm-therapeutics-provides-clinical-update-including-results-from-a-phase-2-study-of-pr013-in-allergic-conjunctivitis-300612160.html

About the Author

has written 39391 stories on this site.

Copyright © 2010 Business and Corporate News.